|
|
Last Modified: 10/31/2007  First Published: 6/1/1997 |
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase II
|
|
|
|
Treatment
|
|
|
|
Closed
|
|
|
|
21 and below
|
|
|
|
NCI
|
|
|
|
POG-9673 CCG-P9673, NCT00002970, P9673
|
|
|
|
|
|
|
|
Last Modified: 4/12/2007  First Published: 10/1/1998 |
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase II
|
|
|
|
Treatment
|
|
|
|
Completed
|
|
|
|
16 and over
|
|
|
|
NCI
|
|
|
|
CLB-19801 SWOG-C19801, NCT00003545, CALGB-19801
|
|
|
|
|
|
|
|
Last Modified: 1/1/2002  First Published: 12/1/1998 |
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase II
|
|
|
|
Treatment
|
|
|
|
Completed
|
|
|
|
18 and over
|
|
|
|
NCI, Pharmaceutical / Industry
|
|
|
|
GW-PGAA2003 CWRU-GLAX-1999, MB-405, NCI-98-C-0164, UCLA-991004701A, NCT00003635
|
|
|
|
|
|
|
|
Last Modified: 3/7/2007  First Published: 4/1/2000 |
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase II
|
|
|
|
Treatment
|
|
|
|
Completed
|
|
|
|
Under 70
|
|
|
|
NCI
|
|
|
|
CALGB-59901 NCT00005080
|
|
|
|
|
|
|
|
Last Modified: 5/12/2005  First Published: 7/1/2000 |
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase II
|
|
|
|
Treatment
|
|
|
|
Completed
|
|
|
|
16 and over
|
|
|
|
NCI
|
|
|
|
MDA-ID-99208 NCI-430, NCT00005950, 430
|
|
|
|
|
|
|
|
Last Modified: 2/6/2006  First Published: 7/1/2000 |
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase II
|
|
|
|
Treatment
|
|
|
|
Completed
|
|
|
|
16 and over
|
|
|
|
NCI
|
|
|
|
MDA-ID-99213 NCI-86, NCT00005982, 86
|
|
|
|
|
|
|
|
Last Modified: 1/25/2008  First Published: 7/1/2000 |
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase II
|
|
|
|
Treatment
|
|
|
|
Closed
|
|
|
|
16 and over
|
|
|
|
NCI
|
|
|
|
SWOG-S0010 NCT00006020, S0010
|
|
|
|
|
|
|
|
Last Modified: 1/2/2008  First Published: 5/1/2001 |
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase II
|
|
|
|
Treatment
|
|
|
|
Completed
|
|
|
|
1 to 21
|
|
|
|
NCI
|
|
|
|
COG-AALL00P2 AALL00P2, NCT00016302
|
|
|
|
|
|
|
|
Last Modified: 5/1/2002  First Published: 2/1/2000 |
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
Phase I
|
|
|
|
Treatment
|
|
|
|
Closed
|
|
|
|
18 and over
|
|
|
|
NCI
|
|
|
|
CLB-69803 NCT00004239, CALGB-69803
|
|
|
|
|
|
|
|
Last Modified: 10/31/2007  First Published: 5/1/1999 |
|
Phase
|
|
|
|
Type
|
|
|
|
Status
|
|
|
|
Age
|
|
|
|
Sponsor
|
|
|
|
Protocol IDs
|
|
|
|
No phase specified
|
|
|
|
Treatment
|
|
|
|
Completed
|
|
|
|
16 and over
|
|
|
|
NCI
|
|
|
|
CTEP-TRC-9701 CWRU-TRC-1499, NCT00003837, TRC-9701
|
|
|
|